Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cost of Revenue: 2017-2024

Historic Cost of Revenue for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Dec 2024 value amounting to $76.7 million.

  • Ultragenyx Pharmaceutical's Cost of Revenue rose 33.16% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.5 million, marking a year-over-year increase of 34.31%. This contributed to the annual value of $76.7 million for FY2024, which is 69.72% up from last year.
  • According to the latest figures from FY2024, Ultragenyx Pharmaceutical's Cost of Revenue is $76.7 million, which was up 69.72% from $45.2 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's 5-year Cost of Revenue high stood at $76.7 million for FY2024, and its period low was $6.1 million during FY2020.
  • For the 3-year period, Ultragenyx Pharmaceutical's Cost of Revenue averaged around $50.1 million, with its median value being $45.2 million (2023).
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Cost of Revenue slumped by 31.96% in 2020, and later spiked by 161.18% in 2021.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Cost of Revenue (Yearly) stood at $6.1 million in 2020, then skyrocketed by 161.18% to $16.0 million in 2021, then soared by 76.91% to $28.3 million in 2022, then soared by 59.64% to $45.2 million in 2023, then soared by 69.72% to $76.7 million in 2024.